T1	Outcomes 113 132	efficacy and safety
T2	Outcomes 450 471	overall response rate
T3	Outcomes 580 644	response rate in prostate lesion, bone and lymph node metastases
T4	Outcomes 725 803	proportion of patients showing a response with regard to serum PSA (CR and PR)
T5	Outcomes 880 910	incidence of adverse reactions
T6	Outcomes 997 1022	no significant difference
T7	Outcomes 1026 1047	overall safety rating
T8	Outcomes 1069 1095	Frequent adverse reactions
T9	Outcomes 1101 1130	gynecomastia and breast pain.
T10	Outcomes 1171 1208	withdrawn due to shortness of breath.
T11	Outcomes 1209 1287	Serum concentrations of LH, testosterone and estradiol increased significantly
